SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R) and interleukin-18 binding ...
Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across multiple soft tissue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback